Becoming the Leader of Drug Regeneration to Bring First-in-class Therapies for Untreated Serious Diseases

About Us

4P-Pharma is a clinical stage biotech company founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies.

The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.

4P-Pharma’s Major Achievements

2014
FOUNDATION
of 4P-Pharma
≥ 350
≥ 350 screened candidates from different source of innovation
≥ 25 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
2014
FOUNDATION
of 4P-Pharma
≥ 350
≥ 350 screened candidates from different source of innovation
≥ 25 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
FOUNDATION
of 4P-Pharma

Our Approach : circular pharmaceutical development

4P-Pharma aims to bring to patients’ curative solutions faster by moving away from current linear pharmaceutical development towards circular one :

  • Linking innovative cellular target to disease’s biology
  • Regenerate active existing drugs
  • Supporting our clinical trials by in silico and data based clinical trials
  • Leveraging on regulatory fast track to target large unmet medical needs

Our Business Model: Translating science to medicines for patients

We aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI tech companies.

Our R&D capabilities within Pasteur Institute at Lille allow us to assess breakthrough innovations by regenerating active drugs as proprietary first-in-class therapies in the new indication.

Once reaching regulatory milestones, we launch single product vehicles (SPVs), in charge of advancing the assets through accelerated clinical development to market approvals and distribution agreements by geographic and therapeutic area.

Sourcing our therapeutic candidates

  • Discovery stage candidates with established MoA
  • Open innovation strategy in cutting-edge tech network (Research centers, Hospitals, Universities, Biotechs and AI tech companies)

Reaching clinical proof of concept

  • Asset Centric Vehicle incorporation supported by solid preclinical package and proprietary IP portfolio
  • Accelerated clinical development through regulatory opportunities (emergency use or conditional market authorization)
  • Distribution agreements by geographic and therapeutic area

Our Daughter Companies

4Living Biotech is dedicated to the clinical development of 4P021, a drug candidate for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications.

We obtained clinical trial authorizations for phase 2b in severe COVID-19 and we are currently conducting in silico phase II clinical trial for ARDS to enlarge patient population (sepsis, pneumonia, etc).

4Moving Biotech is dedicated to the clinical development of 4P004, a disease modifying drug candidate for osteoarthritis showing anti-inflammatory, anti-catabolic and anabolic properties.

4Moving Biotech launched its phase 1 clinical trial on knee OA patients, to assess intra-articular pharmacokinetic and safety of a GLP-1 analog.

Pipeline

Respiratory infection

4P021

4Living Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase II

Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications.

4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.

Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).

Osteoarthritis

4P004

4Moving Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase I

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.

4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.

Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
Phase I trial on OA patients

Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)

Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Our Team

Our team, our key driver for our success

4P-Pharma is a passionate and complementary team of drug developers, combining scientific, clinical, pharmaceutical, financial, and business experts, and sharing the same vision: bring curative therapies to people with serious diseases. 

Our young, human-sized team of 15 employees is always happy to welcome new talents. Each of our employees is amazing, but it is together that we make 4P-Pharma such a dynamic, proactive and creative company.

Our Partners

News

4P-Pharma au BIO US 2023

Meet us in Boston during the Bio US 2023, June 5th to 8th! Roselina Lam, our Business Development and Licensing-in Manager, will be participating at the event, part of the french healthcare delegation ! Schedule a meeting with us !  

Read More

4P-Pharma appoints Mathilde Mérot Director of Regulatory Affairs and Clinical Operations

4P-Pharma is delighted to welcome Mathilde Mérot appointed Director of Regulatory Affairs and Clinical Operations. She has ten years of experience and a background in Pharma and Biotech companies. Her expertise will complement ours to develop and bring curative therapies for serious untreated diseases to patients. About Mathilde Mérot Mathilde Mérot started her career in clinical&hellip

Read More

4Moving Biotech at OARSI 2023

Our subsidiary 4Moving Biotech, was presented at OARSI- World Congress on Osteoarthritis. It was an excellent opportunity to share our subsidiary’s latest progress and development. Our subsidiary Co-founder/CMO Pr. Francis Berenbaum showcased two posters during the OARSI congress. First poster at OA clinical trial symposium on March 16, 2023 Poster title: GLP1 analogues as a&hellip

Read More
Contact us

Send us an e-mail

Lille
Campus de l’Institut Pasteur de Lille
1 Rue du Professeur Calmette
59000 Lille, France
Locate on Maps
Paris
74 rue du Faubourg Saint-Antoine
75012 Paris, France
Locate on Maps
Paris
BEYOND - Relations Presse
43 rue Condorcet 75009 PARIS
Najette Chaib
nchaib@beyondcom.fr
+ 33 6 18 38 11 14
Locate on Maps